How India Exports Ertapenem to the World

In the United States, Ertapenem is approved for various indications, including the treatment of complicated intra-abdominal infections, complicated skin and skin structure infections, and community-acquired pneumonia. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Ertapenem, indicating a competitive generic market. Recent approvals include those granted in March 2025 and July 2025. As of March 2026, there are no active FDA import alerts specifically targeting Ertapenem, suggesting compliance with regulatory standards. The substantial export volume to the U.S., accounting for 54.9% of India's total Ertapenem exports, underscores the significance of the U.S. market for Indian manufacturers.

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicines, including Ertapenem. Ertapenem has received marketing authorization in several EU member states, adhering to the EU's Good Manufacturing Practice (GMP) requirements. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) continues to regulate Ertapenem post-Brexit, ensuring compliance with UK-specific GMP standards. The significant export to Malta (15.7%) reflects the strategic role of certain EU countries in the distribution of pharmaceuticals within the region.

Ertapenem is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its importance in treating priority health conditions. The WHO's inclusion emphasizes the need for its availability and affordability globally. Ertapenem formulations are standardized across major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy.

In India, Ertapenem is classified under Schedule H1 of the Drugs and Cosmetics Rules, indicating that it is a prescription drug subject to specific regulatory controls to prevent misuse. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on Ertapenem as of March 2026, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceuticals; however, Ertapenem is not currently listed among those requiring an export NOC, facilitating smoother international trade.

The primary patents for Ertapenem have expired, leading to increased generic competition globally. This patent expiration has enabled multiple manufacturers to enter the market, contributing to the competitive pricing observed in export data.

In June 2025, the Indian Ministry of Health and Family Welfare revised the National List of Essential Medicines, reaffirming Ertapenem's inclusion, which underscores its critical role in the healthcare system. In October 2025, the NPPA conducted a review of antibiotic pricing, including Ertapenem, but opted not to impose a ceiling price, maintaining market-driven pricing mechanisms. In December 2025, the CDSCO issued updated guidelines for the manufacturing of carbapenem antibiotics, emphasizing stringent quality control measures to ensure product efficacy and safety. In February 2026, the WHO released a report on antimicrobial resistance, highlighting the importance of antibiotics like Ertapenem in combating resistant infections and urging prudent use to preserve their effectiveness. In March 2026, the EMA approved a new generic version of Ertapenem, further increasing competition and potentially reducing prices within the European market.

These developments reflect the dynamic regulatory and market landscape for Ertapenem, emphasizing the need for continuous monitoring to navigate the complexities of international pharmaceutical trade effectively.

Ertapenem, a broad-spectrum carbapenem antibiotic, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in October 2025.

The reliance on Chinese KSMs introduces significant vulnerabilities. For instance, in September 2025, China reduced the prices of 41 APIs and KSMs by 40% to 50%, aiming to undercut Indian manufacturers. This aggressive pricing strategy has adversely affected the competitiveness of Indian API producers, including those manufacturing Ertapenem.

Our proprietary trade data from 2022 to 2026 indicates a high supplier concentration in Ertapenem exports from India. The top five exporters account for 91.4% of the total export value, with EUGIA PHARMA SPECIALITIES LIMITED alone contributing 70.4%. Such concentration poses a significant single-source risk; any disruption in these key suppliers could severely impact global Ertapenem availability.

To mitigate this risk, the Indian government has implemented the Production Linked Incentive (PLI) scheme to boost domestic API production and reduce reliance on imports. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, essential for antibiotics production. While this initiative aims to enhance self-sufficiency, its impact on diversifying Ertapenem suppliers remains to be seen.

Recent geopolitical tensions have further strained the pharmaceutical supply chain. In February 2026, the closure of the Strait of Hormuz due to military conflicts disrupted the movement of oil tankers and cargo ships, affecting the transportation of pharmaceuticals from India. This blockade has led to increased shipping costs and delays, impacting the timely delivery of Ertapenem to key markets.

Additionally, the Red Sea conflict has posed risks to the supply of key pharmaceutical ingredients and chemicals, including APIs shipped from India to the U.S. and Europe. These disruptions have caused price fluctuations and potential shortages in the pharmaceutical industry. (pharmasource.global)

• Diversify Supplier Base: Encourage the development of alternative suppliers for Ertapenem to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Support initiatives like the PLI scheme to bolster domestic manufacturing of APIs and KSMs, decreasing reliance on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans to address potential disruptions due to geopolitical tensions, including identifying alternative shipping routes and logistics partners.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact the pharmaceutical supply chain and proactively implement risk mitigation strategies.

• Engage in International Collaboration: Work with global regulatory bodies and industry partners to share information and coordinate responses to supply chain disruptions.

RISK_LEVEL: HIGH